VivaBioCell

VivaBioCell. Next generation manufacturing
solutions for advanced therapies

NANT 001 System

Seamless transition from R&D to clinical and commercial manufacturing.
Automated cell expansion and harvest. Small- to mid-scale batch sizes.
Assuring product quality and minimizing costs.
Easier cGMP translation and shorter time to market.
The ideal solution for autologous products and redistributed scale-out manufacturing.

NANT 001 System

NANT 001 Cartridge

The components you already know.
Engineered in an easy-to-load, single-use, closed-system for safe and cGMP-compliant cell processing.

NANT 001 Cartridge

NANT 001 Bioreactor

Built-in microscope, confluence estimation and in-process controls.
High medicinal product standardization. Remote access for monitoring, always at your fingertips.

NANT 001 Bioreactor

Latest News

VivaBioCell at World Advanced Therapy and Regenerative Medicine Congress 2018
Come and meet us by Stand 42 at The World Advanced Therapy and Regenerative Medicine Congress 2018 (London, 16-18 May), to learn more on how VivaBioCell can support you in developing small- to mid-scale batch size products with innovative automated solutions for cell-based and and cell-derived product manufacturing! Read more ›

VivaBioCell Webinar on Cell and Gene Therapy Insights
On 8th March 2018 (07:00 PST; 10:00 EST; 15:00 GMT; 16:00 CET) VivaBioCell will be presenting a live webinar about "Meeting scalability challenges for autologous cell-based manufacturing with automated closed-system solutions", which will be hosted by Cell and Gene Therapy Insight, a platform designed to meet the needs of all stakeholders across the global cell and gene therapy community. Go to the event page to learn more and register for free! Read more ›

POR FESR 2014-2020 FVG: OPPORTUNITA' PER UNA CRESCITA SOSTENIBILE.
VivaBioCell is a beneficiary of SISICOR (Sistema Implantare per la Stabilit√† immediata di impianto in Chirurgia Orale di Ricostruzione), a project approved under the POR FESR 2014-2020 Friuli Venezia Giulia. Read more ›